9Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gas- trointestinal transit in healthy male subjects [J]. Aliment Phar- macolTher, 2001, 15 (11): 1745-1751.
10Degen'L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects [J]. Neurogastroenterol Motil, 2005, 17 (6): 821-826.
2Ke M, Tack J, Quigley EM, Zou D, Choi SC, Leelakusolvong S, Liu A, Kim J. Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. J Neurogastroenterol Motil 2014; 20:458-468 [PMID: 25273116 DOI: 10.5056/jnm14029].
3Jadallah KA, Kullab SM, Sanders DS. Constipation- predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 2014; 20:8898-8909 [PMID: 25083062 DOI: 10.3748/wjg.v20.i27.8898].
4Tack J, Camilleri M, Dubois D, Vandeplassche L, Joseph A, Kerstens R. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. Neurogastroenterol Motil 2015; 27:397405 [PMID: 25581251 DOI: 10.1111/nmo.12505].
5Mansour NM, Ghaith O, E1-Halabi M, Sharara AI. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2012; 107: 792-793 [PMID: 22552247 DOI: 10.1038/ajg.2012.26].
